



## SIRION Biotech to be acquired by PerkinElmer

### Torreya advised SIRION on the transaction

Munich, Germany, June 22, 2021

PerkinElmer, Inc. announced it has entered into an agreement to acquire SIRION Biotech GmbH ("SIRION"), a global provider of viral vector-based technologies that drive improved delivery performance for cell and gene therapies. The acquisition is expected to close during the third quarter of 2021.

Founded in 2005, SIRION is a leading commercial supplier of viral vector technologies for gene and cell therapy as well as vaccine development. SIRION develops novel therapeutic viral vectors and uses proprietary technology platforms based on lenti-, adeno-, and adenoassociated viruses, to expedite its customers' advances in drug development. Additionally, SIRION has established a strong licensing portfolio leveraged by over a dozen major pharmaceutical and biotech players researching more than twenty-five diseases and conditions. The addition of SIRION's offerings will complement PerkinElmer's Horizon Discovery portfolio which includes gene editing and modulation tools for CRISPR, CRISPRi and RNAi, custom cell lines for bioproduction and base editing technologies. SIRION will benefit from becoming part of the PerkinElmer portfolio, with increased access to genomics analysis, gene editing and base editing technologies, as well as a strong global infrastructure and reach.

Torreya advised SIRION on the transaction, which highlights both Torreya's expertise in the bioproduction space and deep relationships within the biotech community. Torreya has advised on over 6 pharmaceutical service transactions in the past 4 months, demonstrating our growing pharma services advisory practice.

#### ABOUT SIRION BIOTECH GMBH:

For more information about Sirion, please see: [www.sirion-biotech.com](http://www.sirion-biotech.com)

#### ABOUT PERKINELMER, INC.:

For more information about PerkinElmer, please see: [www.perkinelmer.com](http://www.perkinelmer.com)

#### Deal Press Release

### Torreya Contact

#### PING SHEK

Managing Director | London Office

[ping.shek@torreya.com](mailto:ping.shek@torreya.com) | +44 (0) 207 451 4552 | [BIO](#)



Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 150 Aldersgate Street, London EC1A 4AB. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.